Cargando…

Serum Total Bilirubin and Risk of Cancer: A Swedish Cohort Study and Meta-Analysis

SIMPLE SUMMARY: Several studies published to date have shown inconclusive results in the association between serum bilirubin and risk of site-specific cancer types and overall cancer. Therefore, there is a need to further investigate this association. Data from the large Swedish Apolipoprotein Morta...

Descripción completa

Detalles Bibliográficos
Autores principales: Monroy-Iglesias, Maria J., Moss, Charlotte, Beckmann, Kerri, Hammar, Niklas, Walldius, Goran, Bosco, Cecilia, Van Hemelrijck, Mieke, Santaolalla, Aida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582941/
https://www.ncbi.nlm.nih.gov/pubmed/34771701
http://dx.doi.org/10.3390/cancers13215540
_version_ 1784597101999554560
author Monroy-Iglesias, Maria J.
Moss, Charlotte
Beckmann, Kerri
Hammar, Niklas
Walldius, Goran
Bosco, Cecilia
Van Hemelrijck, Mieke
Santaolalla, Aida
author_facet Monroy-Iglesias, Maria J.
Moss, Charlotte
Beckmann, Kerri
Hammar, Niklas
Walldius, Goran
Bosco, Cecilia
Van Hemelrijck, Mieke
Santaolalla, Aida
author_sort Monroy-Iglesias, Maria J.
collection PubMed
description SIMPLE SUMMARY: Several studies published to date have shown inconclusive results in the association between serum bilirubin and risk of site-specific cancer types and overall cancer. Therefore, there is a need to further investigate this association. Data from the large Swedish Apolipoprotein Mortality Risk (AMORIS) cohort study was used. We found that overall high levels of bilirubin had no association with overall cancer risk. However, a positive association was found between melanoma and breast cancer risk. On the other hand, an inverse association was found between high levels of bilirubin and risk of gynecological and lung cancers. Further studies are required to establish if bilirubin can be used as a biomarker for risk assessment and/or as a novel therapeutic target. ABSTRACT: Bilirubin has strong antioxidant properties that have been hypothesized to be preventive against the development of cancer. Thus, we aimed to investigate the association between serum total bilirubin (STB) and risk of overall and site-specific cancers in the large Swedish Apolipoprotein Mortality Risk (AMORIS) cohort. We also performed a systematic review and meta-analysis for specific cancer types (colorectal, breast and lung). We found no association between high levels of STB and risk of overall cancer. Regarding site-specific cancer, there was an inverse association between increased STB and lung cancer (Hazard Ratio (HR) for the 4th quartile (Q4) vs. Q1: 0.50; 95%CI: 0.44–0.59) and gynecological cancer (HR for Q4 vs. Q1: 0.86; 95%CI: 0.76–0.99). A positive association was found with melanoma (HR for Q4 vs. Q1: 1.25; 95%CI: 1.06–1.47) and breast cancer (HR for Q4 vs. Q1: 1.13; 95%CI: 1.01–1.25) risk. The meta-analysis showed an inverse association between high levels of STB and risk of lung cancer (Relative risk (RR): 0.69; 95%CI: 0.55–0.86). No associations were seen for colorectal and breast cancer risk. Further studies are required to establish if bilirubin can be used as a biomarker for risk assessment and/or as a novel therapeutic target.
format Online
Article
Text
id pubmed-8582941
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85829412021-11-12 Serum Total Bilirubin and Risk of Cancer: A Swedish Cohort Study and Meta-Analysis Monroy-Iglesias, Maria J. Moss, Charlotte Beckmann, Kerri Hammar, Niklas Walldius, Goran Bosco, Cecilia Van Hemelrijck, Mieke Santaolalla, Aida Cancers (Basel) Article SIMPLE SUMMARY: Several studies published to date have shown inconclusive results in the association between serum bilirubin and risk of site-specific cancer types and overall cancer. Therefore, there is a need to further investigate this association. Data from the large Swedish Apolipoprotein Mortality Risk (AMORIS) cohort study was used. We found that overall high levels of bilirubin had no association with overall cancer risk. However, a positive association was found between melanoma and breast cancer risk. On the other hand, an inverse association was found between high levels of bilirubin and risk of gynecological and lung cancers. Further studies are required to establish if bilirubin can be used as a biomarker for risk assessment and/or as a novel therapeutic target. ABSTRACT: Bilirubin has strong antioxidant properties that have been hypothesized to be preventive against the development of cancer. Thus, we aimed to investigate the association between serum total bilirubin (STB) and risk of overall and site-specific cancers in the large Swedish Apolipoprotein Mortality Risk (AMORIS) cohort. We also performed a systematic review and meta-analysis for specific cancer types (colorectal, breast and lung). We found no association between high levels of STB and risk of overall cancer. Regarding site-specific cancer, there was an inverse association between increased STB and lung cancer (Hazard Ratio (HR) for the 4th quartile (Q4) vs. Q1: 0.50; 95%CI: 0.44–0.59) and gynecological cancer (HR for Q4 vs. Q1: 0.86; 95%CI: 0.76–0.99). A positive association was found with melanoma (HR for Q4 vs. Q1: 1.25; 95%CI: 1.06–1.47) and breast cancer (HR for Q4 vs. Q1: 1.13; 95%CI: 1.01–1.25) risk. The meta-analysis showed an inverse association between high levels of STB and risk of lung cancer (Relative risk (RR): 0.69; 95%CI: 0.55–0.86). No associations were seen for colorectal and breast cancer risk. Further studies are required to establish if bilirubin can be used as a biomarker for risk assessment and/or as a novel therapeutic target. MDPI 2021-11-04 /pmc/articles/PMC8582941/ /pubmed/34771701 http://dx.doi.org/10.3390/cancers13215540 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Monroy-Iglesias, Maria J.
Moss, Charlotte
Beckmann, Kerri
Hammar, Niklas
Walldius, Goran
Bosco, Cecilia
Van Hemelrijck, Mieke
Santaolalla, Aida
Serum Total Bilirubin and Risk of Cancer: A Swedish Cohort Study and Meta-Analysis
title Serum Total Bilirubin and Risk of Cancer: A Swedish Cohort Study and Meta-Analysis
title_full Serum Total Bilirubin and Risk of Cancer: A Swedish Cohort Study and Meta-Analysis
title_fullStr Serum Total Bilirubin and Risk of Cancer: A Swedish Cohort Study and Meta-Analysis
title_full_unstemmed Serum Total Bilirubin and Risk of Cancer: A Swedish Cohort Study and Meta-Analysis
title_short Serum Total Bilirubin and Risk of Cancer: A Swedish Cohort Study and Meta-Analysis
title_sort serum total bilirubin and risk of cancer: a swedish cohort study and meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582941/
https://www.ncbi.nlm.nih.gov/pubmed/34771701
http://dx.doi.org/10.3390/cancers13215540
work_keys_str_mv AT monroyiglesiasmariaj serumtotalbilirubinandriskofcanceraswedishcohortstudyandmetaanalysis
AT mosscharlotte serumtotalbilirubinandriskofcanceraswedishcohortstudyandmetaanalysis
AT beckmannkerri serumtotalbilirubinandriskofcanceraswedishcohortstudyandmetaanalysis
AT hammarniklas serumtotalbilirubinandriskofcanceraswedishcohortstudyandmetaanalysis
AT walldiusgoran serumtotalbilirubinandriskofcanceraswedishcohortstudyandmetaanalysis
AT boscocecilia serumtotalbilirubinandriskofcanceraswedishcohortstudyandmetaanalysis
AT vanhemelrijckmieke serumtotalbilirubinandriskofcanceraswedishcohortstudyandmetaanalysis
AT santaolallaaida serumtotalbilirubinandriskofcanceraswedishcohortstudyandmetaanalysis